Kyu Baek

Qureator is transforming oncology drug development by bridging the translation gap between animal models and human trials. Using proprietary open-channel microphysiological systems and patient-derived vascularized organoids, Qureator builds reproducible human in vitro efficacy models that accurately mimic tumor–immune–vascular interactions. These models achieve over 90% validation compared with patient responses and have led to the first FDA IND approval based solely on human efficacy data in cancer. By integrating human-relevant AI with these models, Qureator enables precise prediction of therapeutic synergy and safety, accelerating the discovery of effective, patient-specific cancer treatments.

Medical Diagnostics, Biochemical and Bioanalytical device

Global Device Advanced Technology Center

Fingerprinting Hardware module, Biometrics Solution

Thesis: A Chronic Drug-Delivery Probe with Integrated Thermopneumatic Microvalves and Closed Loop Circuitry, Thesis Advisor: Dr. Kensall D. Wise